Amyloid-β mediates intestinal dysfunction and enteric neurons loss in Alzheimer's disease transgenic mouse

Cell Mol Life Sci. 2023 Nov 6;80(12):351. doi: 10.1007/s00018-023-04948-9.

Abstract

Alzheimer's disease (AD) is traditionally considered as a brain disorder featured by amyloid-β (Aβ) deposition. The current study on whether pathological changes of AD extend to the enteric nervous system (ENS) is still in its infancy. In this study, we found enteric Aβ deposition, intestinal dysfunction, and colonic inflammation in the young APP/PS1 mice. Moreover, these mice exhibited cholinergic and nitrergic signaling pathways damages and enteric neuronal loss. Our data show that Aβ42 treatment remarkably affected the gene expression of cultured myenteric neurons and the spontaneous contraction of intestinal smooth muscles. The intra-colon administration of Aβ42 induced ENS dysfunction, brain gliosis, and β-amyloidosis-like changes in the wild-type mice. Our results suggest that ENS mirrors the neuropathology observed in AD brains, and intestinal pathological changes may represent the prodromal events, which contribute to brain pathology in AD. In summary, our findings provide new opportunities for AD early diagnosis and prevention.

Keywords: Alzheimer's disease; Amyloid-β; Enteric neuronal loss; Gastrointestinal motility; Intestinal contraction.

MeSH terms

  • Alzheimer Disease* / genetics
  • Amyloid beta-Peptides / genetics
  • Animals
  • Gastrointestinal Diseases*
  • Mice
  • Mice, Transgenic
  • Neurons

Substances

  • Amyloid beta-Peptides